Dr. Witt-Enderby, professor of pharmacology, will be partnering with OsteoStrong to run a clinical trial assessing the efficacy of melatonin and/or osteogenic loading on bone health and quality of life in an osteopenic population.
The inventor of osteogenic loading and chief medical director for OsteoStrong, John Jaquish, Ph.D., will visit Pittsburgh January 29-30, 2020 to kick off the study. It will consider the combined and solo effects of melatonin and osteogenic loading on the stimulation of bone remodeling, or bone building.
Bone health is a serious health concern worldwide, with half of all US adults over 50 at risk of breaking a bone due to low bone density. Low bone density leads to increased risk of fractures, the leading cause of death after 65.
OsteoStrong’s ground-breaking robotic technology safely and effectively builds musculoskeletal strength through osteogenic loading. Originally invented as a way to reverse osteoporosis, this technology builds musculoskeletal strength in users at any age and at every fitness level, from an elite athlete to a deconditioned elderly person.
Recruitment will begin in February. For further inquiries, please email Dr. Paula Witt-Enderby: firstname.lastname@example.org.
Founded in 1878, Duquesne is consistently ranked among the nation’s top Catholic universities for its award-winning faculty and tradition of academic excellence. Duquesne, a campus of nearly 9,500 graduate and undergraduate students, has been nationally recognized for its academic programs, community service and commitment to sustainability. Follow Duquesne University on Facebook, Twitter and Instagram.